Although SGLT2 inhibition raises concerns about the risk of hypoglycemia, previous studies reported that SGLT2 inhibition increased glucose loading to the late proximal tubules, enhanced the glucose transport capacity of SGLT1, and limited glucose excretion and the risk of hypoglycemia. This evidence concerns the gene SLC5A1 and Hypoglycemia.